Drug intelligence / Profile preview

BHT006GE

Development stage: Preclinical
Lead developer: Bio-Hybrid Therapeutics
Modality: Antibody-Based Therapeutics

Overview

BHT006GE is a preclinical-stage biologic antibody candidate being developed by Bio-Hybrid Therapeutics for the prevention of severe allergic responses, specifically shellfish anaphylaxis. It is designed as an immune globulin therapy to target and prevent allergic reactive symptoms caused by specific protein allergens at the source.

Beyond the preview

Go deeper on BHT006GE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BHT006GE.